Physician profile
Andre Brutus
NPI 1760425458
$302,606.79
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92K · 2020: $52K · 2021: $59K · 2022: $53K · 2023: $46K · 2024: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Food and Beverage: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,625.00 |
| Food and Beverage | $1,158.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $238,531.02 | 2019-2024 | Dovato, Apretude |
| Janssen Products, Lp | $45,456.87 | 2019-2023 | Symtuza |
| Gilead Sciences, INC. | $14,162.58 | 2019-2023 | |
| Theratechnologies INC. | $1,691.05 | 2019-2023 | Trogarzo, Egrifta |
| Janssen Biotech, INC. | $1,641.44 | 2019-2023 | Symtuza |
| Glaxosmithkline, LLC. | $880.26 | 2019 | |
| Emd Serono, INC. | $181.37 | 2021 | |
| Mannkind Corporation | $62.20 | 2023 | Afrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Brutus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.